YARGESA

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, UK.

Active ingredients

The drug YARGESA contains one active pharmaceutical ingredient (API):

1	Miglustat UNII ADN3S497AZ - MIGLUSTAT
	Miglustat is an inhibitor of glucosylceramide synthase, the enzyme responsible for the first step in the synthesis of most glycolipids, and a pharmacokinetic enzyme stabiliser of cipaglucosidase alfa. Miglustat is indicated for the treatment of adult patients with mild to moderate type 1 Gaucher disease and for the treatment of progressive neurological manifestations in patients with Niemann-Pick type C disease. Also, miglustat must be used in combination with cipaglucosidase alfa for long-term enzyme replacement therapy in adults with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency).
	Read more about Miglustat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
YARGESA Hard capsule	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AX06	Miglustat	A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AX Various alimentary tract and metabolism products
Discover more medicines within A16AX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1742486
FR	Base de données publique des médicaments	68836272
GB	Medicines & Healthcare Products Regulatory Agency	387358
IT	Agenzia del Farmaco	045318019
LT	Valstybinė vaistų kontrolės tarnyba	1082617
PL	Rejestru Produktów Leczniczych	100386829